|Application ||WB, IHC, FC, ICC, E|
|Reactivity||Human, Rat, Monkey|
|Description||The protein encoded by this gene catalyzes the formation of inositol 1,4,5-trisphosphate and diacylglycerol from phosphatidylinositol 4,5-bisphosphate. This reaction uses calcium as a cofactor and plays an important role in the intracellular transduction of receptor-mediated tyrosine kinase activators. For example, when activated by SRC, the encoded protein causes the Ras guanine nucleotide exchange factor RasGRP1 to translocate to the Golgi, where it activates Ras. Also, this protein has been shown to be a major substrate for heparin-binding growth factor 1 (acidic fibroblast growth factor)-activated tyrosine kinase. Two transcript variants encoding different isoforms have been found for this gene.|
|Immunogen||Purified recombinant fragment of human PLCG1 (AA: 1192-1291) expressed in E. Coli.|
|Formulation||Purified antibody in PBS with 0.05% sodium azide|
|Other Names||1-phosphatidylinositol 4, 5-bisphosphate phosphodiesterase gamma-1, 22.214.171.124, PLC-148, Phosphoinositide phospholipase C-gamma-1, Phospholipase C-II, PLC-II, Phospholipase C-gamma-1, PLC-gamma-1, PLCG1, PLC1|
WB~~1/500 - 1/2000
IF~~1/200 - 1/1000
FC~~1/200 - 1/400
IHC~~1/200 - 1/1000
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||PLCG1 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Mediates the production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). Plays an important role in the regulation of intracellular signaling cascades. Becomes activated in response to ligand- mediated activation of receptor-type tyrosine kinases, such as PDGFRA, PDGFRB, FGFR1, FGFR2, FGFR3 and FGFR4. Plays a role in actin reorganization and cell migration.|
|Cellular Location||Cell projection, lamellipodium. Cell projection, ruffle. Note=Rapidly redistributed to ruffles and lamellipodia structures in response to epidermal growth factor (EGF) treatment|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
1.Cancer Discov. 2014 Apr;4(4):OF13.2.Int J Cancer. 2013 Mar 1;132(5):1022-31.
If you have any additional inquiries please email technical services at email@example.com.